Menopause

Metabolite profiling of osteoporosis and atherosclerosis

December 30, 2020

A study in the journal Vascular Health and Risk Management has found significant differences in the metabolite profiling of altered amino acid and lipoprotein metabolism in participants with atherosclerosis and osteoporosis, compared with those in healthy menopausal women.

Vertigo risk factors in perimenopausal women

December 03, 2020

It has yet to be fully elucidated why postmenopausal women have a higher prevalence of benign paroxysmal positional vertigo (BPPV); however, the sudden decrease in estrogen during menopause can cause a rapid decrease in estrogen receptors, which may disturb otoconial metabolism and thus, increase the prevalence of BPPV.

Highlights from NAMS 2020 Virtual Annual Meeting

September 29, 2020

In this video, Senior Editor Angie DeRosa interviews Nanette Santoro, MD, Chair of the 2020 Scientific Program Committee for the Virtual Annual Meeting of the North American Menopause Society (NAMS).

Trauma’s relation to poor sleep and health in midlife women

September 29, 2020

Poor sleep occurs frequently among midlife women, which is significantly linked to childhood and adult trauma, according to a prospective study presented at the 2020 Virtual Annual Meeting of the North American Menopause Society (NAMS).

Cannabis for managing menopause symptoms

September 28, 2020

This article is based on information presented at the 2020 Virtual Annual Meeting of the North American Menopause Society (NAMS). According to NAMS, all presentations have been pre-recorded and now are available for on-demand viewing beginning Sept. 28 through Sept. 21, 2021.

Research finds link between prior depression and severity of symptoms during perimenopause

September 18, 2020

Perimenopausal women with prior depression exhibit significantly more depressive symptoms, more menopausal symptoms, and more sleep disturbances than perimenopausal women without prior depression, according to a study from Switzerland.

Variation in outcome reporting and measurement tools among treatment trials for GSM

August 28, 2020

Considerable heterogeneity exists in reported outcomes and measures used in clinical trials of treatments for genitourinary syndrome of menopause (GSM), which impacts between 40% and 60% of postmenopausal women, according to a systematic review in the journal Menopause.